Company intelligence / Profile preview
AVAX Technologies, Inc.
Philadelphia, Pennsylvania, United Statesavax-tech.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
MVax has shown promising efficacy in melanoma with a five-year OS rate of approximately 44% and response rates around one-third; its pivotal trial is ongoing but enrollment was suspended due to funding issues. OVax demonstrated encouraging safety and survival outcomes in advanced ovarian cancer patients resistant to standard chemotherapy—median survival reached nearly two years without significant toxicity. Both programs leverage AVAX’s autologous vaccine platform and have received Orphan Drug Status.[4][5][8]
- Therapeutic areas
- Oncology
- Modalities
- Autologous cell vaccinesTherapeutic vaccines
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on AVAX Technologies, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVAX Technologies, Inc..